Who is sponsoring NCT03057561?

NCT03057561 is sponsored by Dipan Shah.

What drugs are being tested in NCT03057561?

Interventions in NCT03057561: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA), Cardiac MRI with contrast agent, Gadovist.

What condition does NCT03057561 study?

NCT03057561 studies Coronary Artery Disease, Cardiomyopathy.

Is NCT03057561 still recruiting?

NCT03057561 is currently status unknown. Last updated 22 January 2019.

Last reviewed 2019-01-22 · How we verify

NCT03057561

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Status unknown NA Last updated 22 January 2019

What this trial tests

NA trial testing Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA) in Coronary Artery Disease in 120 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
31 December 2020

30 June 2021

Quick facts

Lead sponsor	Dipan Shah
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	diagnostic
Enrollment	120
Start date	1 October 2016
Primary completion	31 December 2020
Estimated completion	30 June 2021

Drugs / interventions tested

Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA) — full drug profile →
Cardiac MRI with contrast agent, Gadovist — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Cardiomyopathy — all drugs for Cardiomyopathy →

Sponsor

Dipan Shah — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease or Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project is designed to demonstrate equivalence of Dotarem enhanced LGE-CMR (late gadolinium enhancement cardiac MRI) with Gadoviost enhanced LGE-CMR from the standpoint of visual image quality, quantitative image quality, and association with clinical outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Dipan Shah trials

Trials by the same sponsor.

NCT04281823 — DeBakey Cardiovascular Magnetic Resonance Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03057561 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dipan Shah
Last refreshed: 22 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03057561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing